Great Point Partners LLC Takes $1.26 Million Position in Eliem Therapeutics, Inc. (NASDAQ:ELYM)

Great Point Partners LLC purchased a new position in Eliem Therapeutics, Inc. (NASDAQ:ELYM) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 248,168 shares of the company’s stock, valued at approximately $1,263,000. Eliem Therapeutics makes up about 0.4% of Great Point Partners LLC’s holdings, making the stock its 28th largest position.

Several other large investors have also bought and sold shares of ELYM. Rhumbline Advisers bought a new stake in shares of Eliem Therapeutics during the 2nd quarter valued at $59,000. SG Americas Securities LLC purchased a new stake in shares of Eliem Therapeutics in the 3rd quarter worth approximately $60,000. Valence8 US LP bought a new position in Eliem Therapeutics during the 3rd quarter valued at approximately $61,000. Chicago Partners Investment Group LLC purchased a new position in Eliem Therapeutics during the third quarter valued at $81,000. Finally, Dimensional Fund Advisors LP purchased a new stake in shares of Eliem Therapeutics in the second quarter worth $89,000. 69.76% of the stock is owned by institutional investors.

Eliem Therapeutics Price Performance

Shares of Eliem Therapeutics stock opened at $3.04 on Wednesday. The stock has a market cap of $90.45 million, a price-to-earnings ratio of -5.74 and a beta of -0.39. Eliem Therapeutics, Inc. has a 1 year low of $2.35 and a 1 year high of $11.55. The firm’s 50-day moving average is $4.79 and its 200 day moving average is $6.52.

About Eliem Therapeutics

Eliem Therapeutics, Inc, a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.